Bristol-Myers’ Hepatitis C Study Halted on Safety Concerns
10:04 EDT 2 Aug 2012 | PharmPro
Drugmaker Bristol-Myers Squibb Co. is suspending a midstage study of a potential hepatitis C treatment because of a serious patient safety issue.
Original Article: Bristol-Myers’ Hepatitis C Study Halted on Safety Concerns
More From BioPortfolio on "Bristol-Myers’ Hepatitis C Study Halted on Safety Concerns"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
